Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
Chenghao ZhaoZhanwang XiangMingan LiHaofan WangHuan LiuHuzheng YanMingsheng HuangPublished in: Journal of hepatocellular carcinoma (2023)
Atezo/Bev-TACE and LEN-TACE showed comparable efficacy and safety as first-line therapies for unresectable HCC patients.